Ad
related to: katalin kariko mrna technology newsWacker Biotech is a true end-to-end mRNA CDMO with pDNA, mRNA, and LNP capabilities. We offer seamless integration of mRNA manufacturing with pDNA and LNP capabilities.
- Full mRNA Program Support
Wacker Biotech is a true end-to-end
mRNA CDMO with pDNA,...
- Clinical-Grade pDNA
pDNA for AAV, lentivirus, mRNA and
CGT products | GMP plasmids for...
- Commercial-Grade pDNA
PLASMITEC pDNA platform produces
complex plasmids and streamlines...
- Research-Grade pDNA
Unlock pDNA as a critical starting
material for CGT and mRNA- and...
- Reliable pDNA Supply
Wacker Biotech offers GMP pDNA
manufacturing through our...
- mRNA Vaccine Development
We offer seamless integration of
mRNA manufacturing with pDNA and...
- Full mRNA Program Support
Search results
Oct 2, 2023 · Nobel Prize winners Katalin Karikó and Drew Weissman pioneered the technology that produced a Covid-19 vaccine in record time. Next, mRNA could tackle flu, malaria, and HIV.
Oct 2, 2023 · The Nobel Prize in Physiology or Medicine has been awarded to a pair of scientists who developed the technology that led to the mRNA Covid vaccines. Professors Katalin Kariko and Drew...
- Overview
- A new chapter
Download PDF
This year’s Nobel Prize in Physiology or Medicine has been awarded to biochemist Katalin Karikó and immunologist Drew Weissman for discoveries that enabled the development of mRNA vaccines against COVID-19.
The vaccines have been administered billions of times, saved millions of lives and prevented millions of cases of severe COVID-19, said the Nobel committee.
Karikó, who is at Szeged University in Hungary, and Weissman, at the University of Pennsylvania in Philadelphia (UPenn), paved the way for the vaccines’ development by finding a way to deliver genetic material called messenger RNA into cells without triggering an unwanted immune response.
They will each receive an equal share of the prize, which totals 11 million Swedish krona (US$1 million).
Karikó is the 13th female scientist to win a Nobel Prize in medicine or physiology (see ‘Nobel imbalance’). She was born in Hungary, and moved to the United States in the 1980s. “Hopefully, this prize will inspire women and immigrants and all of the young ones to persevere and be resilient. That’s what I hope,” she tells Nature.
The COVID-19 vaccines developed by Moderna and the Pfizer–BioNTech collaboration deliver mRNA that instructs cells to create copies of a protein that is found on SARS-CoV-2 virus particles, called the spike protein. This stimulates the body to make antibodies that target the protein, as well as triggering other immune responses.
The tangled history of mRNA vaccines
Oct 2, 2023 · Biochemists Katalin Karikó and Drew Weissman devised mRNA modifications to make vaccines that trigger good immune responses instead of harmful ones.
Nov 18, 2021 · But the story of how scientist Drew Weissman (MED’87, GRS’87) and his research partner Katalin Karikó developed the revolutionary mRNA technology that powers the world’s most effective COVID-19 vaccines was a much slower burn—one that easily could have flickered out.
- Ting Yu
Oct 2, 2023 · Katalin Karikó and Drew Weissman were awarded this year’s Nobel Prize in Physiology or Medicine for mRNA vaccine discoveries that made highly effective COVID vaccines possible.
People also ask
What did Katalin Karikó and drew Weissman do?
Why did Katalin Karikó and drew Weissman win a Nobel Prize?
Why did Karikó leave mRNA?
Who won the Nobel Prize for mRNA Technology in 2023?
Oct 2, 2023 · Katalin Karikó and Drew Weissman are the recipients of the 2023 Nobel Prize in Medicine. The University of Pennsylvania messenger RNA pioneers whose years of scientific partnership unlocked an understanding of how to modify mRNA to make it an effective therapeutic—enabling a platform used to rapidly develop lifesaving vaccines amid the ...
Ad
related to: katalin kariko mrna technology newsWacker Biotech is a true end-to-end mRNA CDMO with pDNA, mRNA, and LNP capabilities. We offer seamless integration of mRNA manufacturing with pDNA and LNP capabilities.
